Eyetech Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutics to treat diseases of the eye. The company’s Macugen is a pegaptanib sodium injection, which is used for the treatment of neovascular age-related macular degeneration. It has collaboration with Pfizer, Inc. to develop Macugen for the treatment of diabetic macular edema and retinal vein occlusion. The company also has licensing agreement with Gilead Sciences, Inc. and Nektar Therapeutics to develop, manufacture, and commercialize products containing Macugen. Eyetech Pharmaceuticals was co-founded by Marty Glick, David R. Guyer, Samir Patel, and Anthony P. Adamis in 2000. The company is headquartered in New York City. As of November 14, 2005, Eyetech Pharmaceuticals Inc. is a subsidiary of OSI Pharmaceuticals Inc.